BOTHELL, Wash.--(BUSINESS WIRE)--Iverson Genetic Diagnostics, Inc. announced today a partnership agreement with Vanderbilt University under which Iverson receives global exclusive commercialization rights for molecular diagnostics that will help physicians to assess breast cancer risk in women considering hormone replacement therapy during menopause. Research suggests that estrogen metabolites represent one of several determinants of the risk of breast cancer. Specific enzymes regulate the biochemical pathways associated with the metabolism of estrogen. Corresponding genes code for the synthesis of these enzymes. Mutations of these genes are common and have been shown in the work of Fritz Parl, M.D., Ph.D., Philip Crooke, Ph.D., William Dupont, Ph.D., and others to be associated with an increased risk of cancer.
